Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.
STUDY17022 First in Human, Phase 1/1b, Open label, Multicenter Study of Bifunctional EGFR/TGF ß Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR Driven Advanced Solid Tumors The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors. Study Information
STUDY21361 A Phase 1/2 Open label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE) This study will assess the safety and tolerability of multiple dose levels of PC14586 in participants with advanced solid tumors containing a p53 Y220C mutation. Study Information
STUDY21774 A Phase 1/2, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF9001 as a Monotherapy and in Combination with Nivolumab in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indications Determine the maximum tolerated dose (MTD) of DF9001 as a monotherapy and in combination with nivolumab in participants with advanced (unresectable, recurrent, or metastatic) solid tumors. Assess the overall response rate (ORR) according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) per an Independent Endpoint Review Committee (IERC). Study Information
STUDY24160 An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-355 and BBI-355 in Combination with Select Targeted Therapies in Subjects with Locally Advanced or Metastatic Solid Tumors with Oncogene Amplifications To assess the safety, tolerability, and dose-limiting toxicities (DLTs) of BBI-355 as a single agent administered orally at escalating dose levels in adult subjects with locally advanced or metastatic solid tumors with oncogene amplifications. To assess the safety, tolerability, and DLTs ofBBI-355 in combination with each of the following agents: erlotinib, futibatinib, or abemaciclib, at escalating dose levels in adults with locally advanced or metastatic solid tumors with corresponding oncogene amplifications. To determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) of BBI-355 as a single agent. To determine the MTD and the RP2D of BBI-355 in combination with each of the following agents: erlotinib, futibatinib, or abemaciclib. Study Information